Secukinumab (registered by Novartis with the brand name Cosentyx®) and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These biologicals were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
In the Drug Design, Development and Therapy review Marije Koenders summarizes some milestones in the development of secukinumab. As per this review Phase III trials proved the clinical efficacy of this anti-IL-17 antibody in psoriasis, followed by a rapid FDA approval of secukinumab for moderate-to-severe plaque psoriasis.
In rheumatoid arthritis, however, Phase II/III randomized controlled trials failed to demonstrate convincing data that secukinumab is effective in this condition. In contrast, Phase III trials appear to indicate that secukinumab is an efficacious treatment for psoriatic arthritis patients.
Thus, according to Marije Koenders the international treatment guidelines for various rheumatic diseases may need to be updated. Also secukinumab appears to be a novel class of drugs currently available for the treatment for several rheumatic diseases.